TRIB VS ORGS Stock Comparison

Performance

TRIB
10/100

TRIB returned -60.18% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

ORGS
10/100

ORGS returned -74.88% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

TRIB
83/100

3 analysts offer 12-month price targets for TRIB. Together, they have an average target of 0, the most optimistic target put TRIB at 0 within 12-months and the most pessimistic has TRIB at 0.

ORGS
75/100

1 analysts offer 12-month price targets for ORGS. Together, they have an average target of 0, the most optimistic target put ORGS at 0 within 12-months and the most pessimistic has ORGS at 0.

Sentiment

TRIB
67/100

TRIB had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 5.22 posts, 3.44 comments, and 2.83 likes per day.

ORGS

"Sentiment" not found for ORGS

Technicals

TRIB
11/100

TRIB receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

ORGS
11/100

ORGS receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

TRIB
10/100

TRIB has missed earnings 10 times in the last 20 quarters.

ORGS
10/100

ORGS has missed earnings 7 times in the last 20 quarters.

Profit

TRIB
48/100

Out of the last 20 quarters, TRIB has had 14 profitable quarters and has increased their profits year over year on 4 of them.

ORGS
13/100

Out of the last 20 quarters, ORGS has had 1 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

TRIB
50/100

TRIB has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

ORGS
50/100

ORGS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Trinity Biotech plc Summary

Nasdaq / TRIB

Healthcare

Medical - Diagnostics & Research

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Orgenesis Inc. Common Stock Summary

Nasdaq / ORGS

Healthcare

Biotechnology

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Power up your portfolio